Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles

Carcaboso, Ángel M.; Hernandez, Rufo Sánchez; Igartua, Manoli; Rosas, Juan M.; Patarroyo, Manuel E.; Pedraz, José Luís

doi:10.1016/j.vaccine.2003.10.020

Cited by 87 publications

(50 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two PLGA copolymers (Resomer ® RG503 and RG756) with different lactide/glycolide ratio, 50:50 and 75:25 (6-12 weeks and over than 18 weeks degradation rate, respectively), were selected to carry out the studies. As expected, based on previously reported works 2004b), no influence of the polymer type used was observed either relative to the microsphere physical characteristics, mean distribution size, and zeta potential, or regarding peptide entrapment, total antigen load, and surface adsorbed peptide. The only difference found between both PLGA MP formulations was the antigen release profile, as was shown by the peptide in vitro release study.…”

Section: Discussionsupporting

confidence: 88%

Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides

Mata¹,

Igartua²,

Hernández³

et al. 2010

Drug Delivery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides

Mata¹,

Igartua²,

Hernández³

et al. 2010

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…However, SPf66 loaded NPs showed a poor immunogenicity only superior to the free peptide group. 74 Wendorf et al revealed that PLGA NPs and MPs, with 110 nm and 800-900 nm in diameter, respectively, are similar in eliciting immune response according to IgG titers in mice. 16 The results of a study conducted by Thomas et al confirmed that HBsAg-loaded PLGA MSs in »5 mm diameter could elicit a more robust immune response when compared to those with a 12 mm diameter.…”

Section: Environmental Related Factorsmentioning

confidence: 99%

Peptide/protein vaccine delivery system based on PLGA particles

Allahyari

Mohit

2015

Human Vaccines & Immunotherapeutics

179

118

View full text Add to dashboard Cite

Due to the excellent safety profile of poly (D,L-lactide-co-glycolide) (PLGA) particles in human, and their biodegradability, many studies have focused on the application of PLGA particles as a controlled-release vaccine delivery system. Antigenic proteins/peptides can be encapsulated into or adsorbed to the surface of PLGA particles. The gradual release of loaded antigens from PLGA particles is necessary for the induction of efficient immunity. Various factors can influence protein release rates from PLGA particles, which can be defined intrinsic features of the polymer, particle characteristics as well as protein and environmental related factors. The use of PLGA particles encapsulating antigens of different diseases such as hepatitis B, tuberculosis, chlamydia, malaria, leishmania, toxoplasma and allergy antigens will be described herein. The co-delivery of antigens and immunostimulants (IS) with PLGA particles can prevent the systemic adverse effects of immunopotentiators and activate both dendritic cells (DCs) and natural killer (NKs) cells, consequently enhancing the therapeutic efficacy of antigen-loaded PLGA particles. We will review co-delivery of different TLR ligands with antigens in various models, highlighting the specific strengths and weaknesses of the system. Strategies to enhance the immunotherapeutic effect of DCbased vaccine using PLGA particles can be designed to target DCs by functionalized PLGA particle encapsulating siRNAs of suppressive gene, and disease specific antigens. Finally, specific examples of cellular targeting where decorating the surface of PLGA particles target orally administrated vaccine to Mcells will be highlighted.

show abstract

“…However, previous studies with malaria parasites (1,5,15,23,24,27,30) and Japanese encephalitis virus (unpublished data), which are prototypical mosquito-borne infectious protozoa and virus, respectively, indicated that mucosal vaccines could be effective alternative immunization methods.…”

mentioning

confidence: 99%

Nasal Immunization with a Malaria Transmission-Blocking Vaccine Candidate, Pfs25, Induces Complete Protective Immunity in Mice against Field Isolates of Plasmodium falciparum

et al. 2005

View full text Add to dashboard Cite

Malaria transmission-blocking vaccines based on antigens expressed in sexual stages of the parasites are considered one promising strategy for malaria control. To investigate the feasibility of developing noninvasive mucosal transmission-blocking vaccines against Plasmodium falciparum, intranasal immunization experiments with Pichia pastoris-expressed recombinant Pfs25 proteins were conducted. Mice intranasally immunized with the Pfs25 proteins in the presence of a potent mucosal adjuvant cholera toxin induced robust systemic as well as mucosal antibodies. All mouse immunoglobulin G (IgG) subclasses except IgG3 were found in serum at comparable levels, suggesting that the immunization induced mixed Th1 and Th2 responses. Consistent with the expression patterns of the Pfs25 proteins in the parasites, the induced immune sera specifically recognized ookinetes but not gametocytes. In addition, the immune sera recognized Pfs25 proteins with the native conformation but not the denatured forms, indicating that mucosal immunization induced biologically active antibodies capable of recognizing conformational epitopes of native Pfs25 proteins. Feeding Anopheles dirus mosquitoes with a mixture of the mouse immune sera and gametocytemic blood derived from patients infected with P. falciparum resulted in complete interference with oocyst development in mosquito midguts. The observed transmission-blocking activities were strongly correlated with specific serum antibody titers. Our results demonstrated for the first time that a P. falciparum transmission-blocking vaccine candidate is effective against field-isolated parasites and may justify the investigation of noninvasive mucosal vaccination regimens for control of malaria, a prototypical mucosa-unrelated mosquito-borne parasitic disease.

show abstract

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles

Cited by 87 publications

References 46 publications

Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides

Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides

Peptide/protein vaccine delivery system based on PLGA particles

Nasal Immunization with a Malaria Transmission-Blocking Vaccine Candidate, Pfs25, Induces Complete Protective Immunity in Mice against Field Isolates of Plasmodium falciparum

Contact Info

Product

Resources

About